Publications by authors named "Jeff Sevigny"

Claim this Profile
A
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Gennaro Pagano, Frank G Boess, Kirsten I Taylor, Benedicte Ricci, Brit Mollenhauer, Jeff Sevigny

Front Neurol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms.
Daniel Umbricht, Markus Abt, Paul Tamburri, Christopher Chatham, Štefan Holiga, Jeff Sevigny

Biol Psychiatry Glob Open Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The definition of neuronopathic Gaucher disease.
Raphael Schiffmann, Jeff Sevigny, Arndt Rolfs, Elin Haf Davies, Ozlem Goker-Alpan

J Inherit Metab Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
Federico Bolognani, Marta Del Valle Rubido, Lisa Squassante, Christoph Wandel, Michael Derks, Jeff Sevigny

Sci Transl Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with autism spectrum disorders display reproducible functional connectivity alterations.
Štefan Holiga, Joerg F Hipp, Christopher H Chatham, Pilar Garces, Will Spooren, Jeff Sevigny

Sci Transl Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of 3 Novel Tau Radiopharmaceuticals, C-RO-963, C-RO-643, and F-RO-948, in Healthy Controls and in Alzheimer Subjects.
Dean F Wong, Robert A Comley, Hiroto Kuwabara, Paul B Rosenberg, Susan M Resnick, Jeff Sevigny

J Nucl Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams

Nature· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.
Jeff Sevigny, Joyce Suhy, Ping Chiao, Tianle Chen, Gregory Klein

Alzheimer Dis Assoc Disord· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.
James Ferrero, Leslie Williams, Heather Stella, Kate Leitermann, Alvydas Mikulskis, Jeff Sevigny

Alzheimers Dement (N Y)· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams

Nature· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
Jae-Hong Lee, Jeff Sevigny

Alzheimer Dis Assoc Disord· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis